Sociedad Americana de Hirudoterapia

Агенција за лекови и медицински средства на Република Северна Македонија

MALMED · North Macedonia · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

North Macedonia's Agency for Medicinal Products and Medical Devices — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
North Macedonia
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Macedonian Law on Medicinal Products and Medical Devices (Official Gazette No. 106/2007, as amended)
  • Macedonian national medical device regulatory framework (progressively aligning with EU MDR 2017/745)

Prescriber Requirements

  • Macedonian Chamber of Physicians–registered doctor — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

MALMED registration as applicable; Macedonian-language labelling. Standard cold-chain conditions.

Import/Export Rules

MALMED and Food and Veterinary Agency clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Macedonian Health Insurance Fund (FZOM) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Macedonian regulation is progressively converging toward the EU acquis as part of the EU accession process; whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.